| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Small hepatocyte-like progenitor cells (SHPCs) transiently appear in rat livers treated with retrorsine (Ret)/70% partial hepatectomy (PH). We reported that transplantation of Thy1+ cells derived from galactosamine-treated liver accelerated the growth of SHPCs in Ret/PH-treated rat livers. Extracellular vesicles (EVs) produced by Thy1+ donor cells activated SHPCs. As bone marrow-derived mesenchymal cells (BM-MCs) also express Thy1, we investigated whether BM-MCs could promote the growth of SHPCs as well as hepatic Thy1+ cells. EVs isolated from conditioned medium of cultured BM-MCs were administrated into Ret/PH-treated rat livers, resulting in the growth of SHPCs. Soluble factors contained in EVs were examined and we identified that miRNA146a is the most important factor for enhancing the proliferation of cultured small hepatocytes (SHs). EVs derived from BM-MCs carry miR146a into SHPCs for activating their growth capacity.
|
